Skip to main content
SpringerLink
Log in

Impact of renal function on argatroban therapy during percutaneous coronary intervention

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI). We investigated the effect of renal function on argatroban therapy during PCI. From previous argatroban studies in PCI, we evaluated relationships between estimated creatinine clearance (CrCl) and activated clotting times (ACTs), dosage, and outcomes in 219 patients with or at risk of HIT (HIT group, n = 67) or administered glycoprotein IIb/IIIa inhibition (non-HIT group, n = 152). Patients received an argatroban bolus (350 mcg/kg, HIT group; 250 or 300 mcg/kg, non-HIT group) then 25–30 mcg/kg/min (adjusted to achieve ACTs 300–450 s, HIT group) or 15 mcg/kg/min (target ACTs 275–325 s, non-HIT group), with additional 150-mcg/kg boluses if needed. Of 219 patients, 55 (25%) had CrCl ≤ 60 ml/min (8 with CrCl ≤ 30 ml/min). Regression analyses detected no association between CrCl (range 7–231 ml/min) and initial ACT (by bolus) or mean infusion dose. Multi-bolus usage was similar in patients with, versus without, CrCl ≤ 60 ml/min. In the non-HIT group, CrCl was associated (P = 0.01) with the time to ACT ≤ 160 s after argatroban cessation (~17 min slower per 30-ml/min CrCl decrease). Eight patients (none with CrCl ≤ 60 ml/min) had ischemic complications. Three patients (1 with CrCl 40 ml/min) experienced major bleeding. Argatroban dose adjustment for renal function appears unnecessary during PCI. Renal dysfunction may be associated with slower (by minutes) ACT effect decay after argatroban cessation. Argatroban is well tolerated in PCI patients with renal impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Warkentin TE, Greinacher A, Koster A, Lincoff AM (2003) Treatment and prevention of heparin-induced thrombocytopenia: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):340S–380S

    Article  Google Scholar 

  2. Keeling D, Davidson S, Watson H (2006) The management of heparin-induced thrombocytopenia. Br J Haematol 133:259–269

    Article  CAS  PubMed  Google Scholar 

  3. Levy JH, Tanaka KA, Hursting MJ (2007) Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. Anesth Analg 105:570–582

    Article  CAS  PubMed  Google Scholar 

  4. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F (2002) Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 57:177–184

    Article  PubMed  Google Scholar 

  5. Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shaley Y, Ver Lee P, Traverse JH, Rodriquez AR, Ohman EM, Harrington RA, Califf RM (2003) The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 15:611–616

    PubMed  Google Scholar 

  6. Swan SK, Hursting MJ (2000) The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20:318–329

    Article  CAS  PubMed  Google Scholar 

  7. Izawa O, Katsuki M, Komatsu T, Iida S (1986) Pharmacokinetics studies of argatroban (MD805) in human—concentrations of argatroban and its metabolites in plasma, urine, and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 14(Suppl 5):251–263

    Google Scholar 

  8. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang I-K, Rifkin SD, Moran J, Hursting MJ, Kelton JG (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838–1843

    CAS  PubMed  Google Scholar 

  9. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849–1856

    Article  CAS  PubMed  Google Scholar 

  10. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F (2006) Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129:1407–1416

    Article  CAS  PubMed  Google Scholar 

  11. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ, Healy JL, Watanabe H, Osakabe M, Yeh R, Jang IK (2008) Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis 25:214–218

    Article  CAS  PubMed  Google Scholar 

  12. Jang IK, Lewis BE, Matthai WH, Kleiman NS (2004) Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis 18:31–37

    Article  CAS  PubMed  Google Scholar 

  13. Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C, Mackie K, Chan C, Dzavik V (2006) Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J 151:146–152

    Article  PubMed  Google Scholar 

  14. Roguin A, Steinberg BA, Watkins SP, Resar JR (2005) Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function. Int J Cardiovasc Interven 7:88–92

    Google Scholar 

  15. Osten MD, Ivanov J, Eichhofer J, Seidelin PH, Ross JR, Barolet A, Horlick EM, Ing D, Schwartz L, Mackie K, Dzavik V (2008) Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention. Am J Cardiol 101:780–785

    PubMed  Google Scholar 

  16. Mathis AS, Gugger JJ (2005) Percutaneous coronary intervention-related bleeding risk factors in current practice. Ann Pharmacother 39:1627–1633

    Article  PubMed  Google Scholar 

  17. O’Shea SI, Ortel TL, Kovalik EC (2003) Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 16:61–67

    Article  PubMed  Google Scholar 

  18. McIntosh BA (2002) Developing an algorithm for treating heparin-induced thrombocytopenia. Clin Adv Hematol Oncol 2:216–222

    Google Scholar 

  19. Hursting MJ, Murray PT (2008) Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron Clin Pract 109:c80–c94

    Article  PubMed  Google Scholar 

  20. Murray PM, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, Tang I, Hursting MJ, Shamp TR, Swan SK (2004) A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66:2446–2453

    Article  CAS  PubMed  Google Scholar 

  21. Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT (2005) Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 39:231–236

    Article  CAS  PubMed  Google Scholar 

  22. Arpino PA, Hallisey RK (2004) Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 38:25–29

    Article  CAS  PubMed  Google Scholar 

  23. Guzzi LM, McCollum DA, Hursting MJ (2006) Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 22:169–176

    Article  CAS  PubMed  Google Scholar 

  24. Cox DS, Kleiman NS, Boyle DA, Aluri J, Parchman LG, Holdbrook F, Fossler MJ (2004) Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein Ilb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol 44:981–990

    Article  CAS  PubMed  Google Scholar 

  25. Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J (2002) Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost 8:217–224

    Article  CAS  PubMed  Google Scholar 

  26. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    Article  CAS  PubMed  Google Scholar 

  27. Hursting MJ, Jang IK (2008) Effect of body mass index on argatroban therapy during percutaneous coronary intervention. J Thromb Thrombolysis 25:273–279

    Article  PubMed  Google Scholar 

  28. Lincoff AM, BIttl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IK, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betrin A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Fevter PJ, Vahanian A, Topol EJ (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 289:853–863

    Article  CAS  PubMed  Google Scholar 

  29. Cruz-Gonzalez I, Sanchez-Ledesma M, Osakabe M, Watanabe H, Baron SJ, Healy JL, Yeh RW, Jang IK (2008) What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention? Blood Coag Fibrinolysis 19:401–404

    Article  CAS  Google Scholar 

  30. Levine R, Hursting MJ, McCollum D (2006) Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 129:5–1167

    Article  Google Scholar 

  31. Begelman SM, Baghdasarian SB, Singh I, Milittelo MA, Hursting MJ, Bartholomew JR (2008) Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J Intensive Care Med 23:313–320

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Science Consulting, Austin, TX, USA

    Marcie J. Hursting

  2. Cardiology Division, Massachusetts General Hospital, Bigelow 800, 55 Fruit Street, Boston, MA, 02114, USA

    Ik-Kyung Jang

Authors
  1. Marcie J. Hursting
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ik-Kyung Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ik-Kyung Jang.

Additional information

Disclosure

M. J. Hursting received consultancy fees from GlaxoSmithKline. I.-K. Jang has nothing to disclose. The authors have full control of all primary data and agree to allow the journal to review the data if requested.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hursting, M.J., Jang, IK. Impact of renal function on argatroban therapy during percutaneous coronary intervention. J Thromb Thrombolysis 29, 1–7 (2010). https://doi.org/10.1007/s11239-009-0357-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-009-0357-8

Keywords

Search

Navigation